{Reference Type}: Case Reports
{Title}: A new case of myelodysplastic syndrome associated with t(3;3)(q21;q26) and inv(11)(p15q22).
{Author}: Monti V;Bagnoli F;Bolli N;Vittoria L;Stioui S;Moiraghi ML;Pruneri G;Testi MA;
{Journal}: Tumori
{Volume}: 106
{Issue}: 6
{Year}: Dec 2020
{Factor}: 2.149
{DOI}: 10.1177/0300891620949666
{Abstract}: <B>UNASSIGNED: </B>Myeloid malignancies are associated with a number of recurrent and sporadic rearrangements that may be oncogenic by ensuring growth advantage and/or increased survival. t(3;3)(q21;q26) has been recognized as a recurrent abnormality in myelodysplastic syndromes (MDS) with poor prognostic significance. Inversion of chr(11) engendering NUP98-DDX10 chimeric product is sporadic and usually associated with diseases with poor prognosis (therapy-related myeloid neoplasm). To date, these cytogenetic abnormalities have been described as isolated events.<BR><B>UNASSIGNED: </B>We report the first case of an 80-year-old man with high-risk MDS harboring a translocation t(3,3)(q21q26) jointly with an inv(11)(p15q22) detected by fluorescent in situ hybridization analysis and conventional cytogenetic techniques.<BR><B>UNASSIGNED: </B>A similar pattern of acquisition was never described before in MDS. The coexistence of two independent, high-risk oncogenic, rare events in the same clone suggests that there may be a functional constraint for synergy between the two events, leading to a proliferative advantage and suggests the utility of extended genotyping in myeloid malignancies.